Nymox Pharmaceutical Corporation (NYMX): Price and Financial Metrics
NYMX Price/Volume Stats
|Current price||$0.20||52-week high||$0.74|
|Prev. close||$0.25||52-week low||$0.17|
|Day high||$0.22||Avg. volume||94,622|
|50-day MA||$0.39||Dividend yield||N/A|
|200-day MA||$0.38||Market Cap||18.10M|
NYMX Stock Price Chart Interactive Chart >
Nymox Pharmaceutical Corporation (NYMX) Company Bio
Nymox Pharmaceutical Corporation engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimers disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in Phase III clinical trials for the treatment of enlarged prostate or benign prostatic hyperplasia, as well as is in Phase II clinical trial for low grade localized prostate cancer. The company was founded in 1989 and is based in Nassau, The Bahamas.
NYMX Latest News Stream
|Loading, please wait...|
NYMX Latest Social Stream
View Full NYMX Social Stream
Latest NYMX News From Around the Web
Below are the latest news stories about NYMOX PHARMACEUTICAL CORP that investors may wish to consider to help them evaluate NYMX as an investment opportunity.
IRVINE, Calif., July 07, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is providing information to address requests it has received for further information concerning recent changes to the Company’s Board of Directors (“Board”) and the Company’s management. Two former employees (the “Former Employees”) of the Company proposed to the Company a potential transaction (the “Proposed Transaction”). The Company, its employees, and the Former Employees
It's time to start the day off right with a breakdown of the biggest pre-market stock movers traders need to watch on Thursday!
Kazia Therapeutics (KZIA) stock is on the move Thursday after the company received fast-track designation for its paxalisib program.
Nymox Pharmaceutical (NYMX) stock is falling on Thursday after the company told investors its shares will be delisted tomorrow.
IRVINE, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) today received a Nasdaq Hearing Delist Decision, noting that Nymox has not regained the required $1.00 share price within the 6-month extension period granted by Nasdaq, and hence the Company's shares will be suspended from trading on NASDAQ at the open of business on July 7, 2023. Nymox shares will be moved to the OTC market. The mechanics of trading the stock remain the same, as do
NYMX Price Returns
Continue Researching NYMXHere are a few links from around the web to help you further your research on Nymox Pharmaceutical Corp's stock as an investment opportunity:
Nymox Pharmaceutical Corp (NYMX) Stock Price | Nasdaq
Nymox Pharmaceutical Corp (NYMX) Stock Quote, History and News - Yahoo Finance
Nymox Pharmaceutical Corp (NYMX) Stock Price and Basic Information | MarketWatch